Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3715751 | 0.86 | LMNA (0.34) | LMNAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31177281 | 0.78 | LRRK2 (0.40) | LRRK2PDE4D | |
| SCHEMBL3713449 | 0.78 | LRRK2 (0.40) | LRRK2 | |
| SCHEMBL3712173 | 0.76 | LMNA (0.49) | LMNAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21087557 | 0.76 | LRRK2 (0.53) | LRRK2 | |
| SCHEMBL3713882 | 0.74 | CDK4 (0.48) | LRRK2 | |
| SCHEMBL1284361 | 0.71 | TBK1 (0.40) | LRRK2 | |
| SCHEMBL21087554 | 0.71 | LRRK2 (0.40) | LRRK2 | |
| SCHEMBL24151605 | 0.70 | MCL1 (0.39) | PDE4BPDE4D | |
| SCHEMBL3721125 | 0.70 | WEE1 (0.46) | LRRK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403853-B1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2013-08-14 | — | — | EP | disclosed |
| WO-2010100431-A1 | PYRROLOPYRIMIDINES USED AS KINASE INHIBITORS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-10 | — | — | WO | disclosed |